Incanthera
WHAT WE DO

A revolutionary dermatology and oncology company

Incanthera is committed to the development of novel treatments for solid tumours (cancers), and licensing these to large pharmaceutical companies.

View what we do
SOL

Our most advanced program

The Company’s current lead product and focus is Sol, which the Company acquired in September 2018. Sol is a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers.

Find out more about Sol

Investors

Regulatory News
View regulatory news

Latest News & Media

Press Coverage
September 02nd, 2022

Incanthera still in discussions over commercial deal for cancer cream Sol

Read more
Webinar
September 23rd, 2021

Watch the Life Sciences Investor Forum

Read more
News
December 07th, 2022

Half-yearly results for the six months ended 30 September 2022

Read more
View All News And Media